Surfactant therapy for patients with ARDS after cardiac surgery. / Bautin, Andrey; Khubulava, Genady; Kozlov, Igor; Poptzov, Vitally; Osovskikh, Victor; Seiliev, Andrey; Volchkov, Vladimir; Rosenberg, Oleg.
In: Journal of Liposome Research, Vol. 16, No. 3, 01.09.2006, p. 265-272.Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - Surfactant therapy for patients with ARDS after cardiac surgery
AU - Bautin, Andrey
AU - Khubulava, Genady
AU - Kozlov, Igor
AU - Poptzov, Vitally
AU - Osovskikh, Victor
AU - Seiliev, Andrey
AU - Volchkov, Vladimir
AU - Rosenberg, Oleg
N1 - Funding Information: 1Cardiovascular-surgery Clinic of the Military Medical Academy, Saint-Petersburg, Russia 2Department of Anesthesiology and Resuscitation of the Institute of Transplantology and Artificial Organs, Ministry of Health, Moscow, Russia 3Department of Endovascular Surgery, Saint-Petersburg, Russia 4Department of Medical Biotechnology of the Central Research Institute of Roentgenology and Radiology, Ministry of Health, Saint-Petersburg, Russia
PY - 2006/9/1
Y1 - 2006/9/1
N2 - This multicenter study investigated the possibility of reducing mortality rate by administering natural lung surfactant additional to standard therapy to treat patients after cardiac surgery who developed an acute respiratory failure (ARDS/ALI). A total of 78 patients (1998-2002) diagnosed with ALI or ARDS were enrolled in the study; patients were considered for study entry only if they developed ALI/ARDS within 72h after cardiac surgery. A total of 36 patients (2000-2002) received Surfactant-BL via bronchoscope at a dose of 3 mg/kg twice a day, and 42 patients (1998-2000) served as the historical control. Within 24h after the first Surfactant-BL administration the PaO2/FiO2 ratio increased from (mean ± SEM) 129.7 ± 9.9 mm Hg to 187.6 ± 17.6 mm Hg (p < 0.01), FiO2 decreased from (mean ± SEM) 0.71 ± 0.03 to 0.56 ± 0.03 (p < 0.01), and 69.4% of the patients treated with surfactant were weaned from the ventilator compared with 50% of the control group during a 28-day period. The mortality rate among patients treated with Surfactant-BL was 30.6% compared with 50% in the control group. In conclusion, early administration of Surfactant-BL leads to the reduction of mortality in cardiac patients who develop postoperatively an ALI or ARDS.
AB - This multicenter study investigated the possibility of reducing mortality rate by administering natural lung surfactant additional to standard therapy to treat patients after cardiac surgery who developed an acute respiratory failure (ARDS/ALI). A total of 78 patients (1998-2002) diagnosed with ALI or ARDS were enrolled in the study; patients were considered for study entry only if they developed ALI/ARDS within 72h after cardiac surgery. A total of 36 patients (2000-2002) received Surfactant-BL via bronchoscope at a dose of 3 mg/kg twice a day, and 42 patients (1998-2000) served as the historical control. Within 24h after the first Surfactant-BL administration the PaO2/FiO2 ratio increased from (mean ± SEM) 129.7 ± 9.9 mm Hg to 187.6 ± 17.6 mm Hg (p < 0.01), FiO2 decreased from (mean ± SEM) 0.71 ± 0.03 to 0.56 ± 0.03 (p < 0.01), and 69.4% of the patients treated with surfactant were weaned from the ventilator compared with 50% of the control group during a 28-day period. The mortality rate among patients treated with Surfactant-BL was 30.6% compared with 50% in the control group. In conclusion, early administration of Surfactant-BL leads to the reduction of mortality in cardiac patients who develop postoperatively an ALI or ARDS.
KW - ALI
KW - ARDS
KW - Open heart operation
KW - Post-bypass lung injury
KW - Surfactant
UR - http://www.scopus.com/inward/record.url?scp=33748498431&partnerID=8YFLogxK
U2 - 10.1080/08982100600850997
DO - 10.1080/08982100600850997
M3 - Article
C2 - 16952880
AN - SCOPUS:33748498431
VL - 16
SP - 265
EP - 272
JO - Journal of Liposome Research
JF - Journal of Liposome Research
SN - 0898-2104
IS - 3
ER -
ID: 85030430